ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data [Yahoo! Finance]
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children [Yahoo! Finance]
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology [Yahoo! Finance]
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Leonard Keith R
Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Welgus Howard G.
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Edwards Larry Todd
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Watanabe Todd
Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Matsuda Masaru
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.